erlotinib hydrochloride has been researched along with Mesothelioma in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, J; De Perrot, M; Fujino, K; Hatanaka, KC; Hatanaka, Y; Hu, HP; Jin, CS; Kaga, K; Kanno, H; Kato, T; Lee, D; Matsui, Y; Matsuno, Y; Ujiie, H; Wada, H; Weersink, RA; Wilson, BC; Wu, L; Yasufuku, K; Zheng, G | 1 |
| Hejduk, K; Pochop, L | 1 |
| Fidias, P; Jackman, DM; Jänne, PA; Johnson, BE; Kindler, HL; Lucca, J; Morse, LK; Ostler, PA; Salgia, R; Yeap, BY | 1 |
| Carreau, JH; Foster, JM; Gatalica, Z; Govindarajan, V; Loggie, BW; Nath, SK; Radhakrishna, U; Sharma, P | 1 |
| Ashai, A; Avital, I; Hassan, R; Kalra, N; Raffeld, M; Xi, L; Zhang, J | 1 |
| Altomare, DA; Borden, EC; Gandara, DR; Garland, LL; Klein-Szanto, AJ; Nagle, RB; Rankin, C; Rivkin, SE; Scott, KM; Testa, JR | 1 |
2 trial(s) available for erlotinib hydrochloride and Mesothelioma
| Article | Year |
|---|---|
Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Disease-Free Survival; Erlotinib Hydrochloride; Feasibility Studies; Female; Humans; Male; Mesothelioma; Middle Aged; Pleural Neoplasms; Quinazolines; Survival Rate | 2008 |
Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Male; Mesothelioma; Middle Aged; Pleural Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Treatment Outcome | 2007 |
4 other study(ies) available for erlotinib hydrochloride and Mesothelioma
| Article | Year |
|---|---|
Preclinical investigation of folate receptor-targeted nanoparticles for photodynamic therapy of malignant pleural mesothelioma.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Female; Folate Receptor 1; Humans; Lipids; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Mice, Nude; Middle Aged; Nanoparticles; Photochemotherapy; Pleural Neoplasms; Porphyrins; Protein Kinase Inhibitors; Treatment Outcome; Xenograft Model Antitumor Assays | 2018 |
[Report from a small registry-permetrexed, tarceva and yondelis].
Topics: Antineoplastic Agents; ErbB Receptors; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Mesothelioma; Pancreatic Neoplasms; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Registries; Sarcoma | 2013 |
Clinical implications of novel activating EGFR mutations in malignant peritoneal mesothelioma.
Topics: DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Mesothelioma; Mutation; Peritoneal Neoplasms; Polymerase Chain Reaction; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome | 2010 |
Patients with peritoneal mesothelioma lack epidermal growth factor receptor tyrosine kinase mutations that would make them sensitive to tyrosine kinase inhibitors.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Female; Genes, erbB-1; Humans; Lung Neoplasms; Male; Mesothelioma; Middle Aged; Mutation; Peritoneal Neoplasms; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Quinazolines | 2012 |